EU will not renew AstraZeneca and Johnson & Johnson contracts

This April 15, 2021 article published by the Business Standard reports on a recent statement released by the European Union (EU) regarding the vaccine contracts with AstraZeneca and Johnson & Johnson (J&J). “The European Commission, in agreement with the leaders of many (EU) countries, has decided that the contracts with the companies that produce (viral vector) vaccines that are valid for the current year will not be renewed at their expiry”. They add that they would now focus on mRNA vaccines.

The article also reports on recent news that Denmark has dropped the AstraZeneca vaccine from its inoculation program following the recent statement from the European Medicines Agency linking the jab to blood clotting [see EMA confirms: AstraZeneca vaccine linked to rare blood clots].

Editor’s Note: We knew that Pfizer and Moderna would become winners in the COVID vaccine race because they had better damage control strategies. Government agencies failed to investigate on reports of deaths and other adverse effects following vaccination. The “effectiveness and safety” of the experimental mRNA vaccines is not real, instead, they were “established” because the US drug regulator turned a blind eye. If they only looked at the science, then they would have seen that the experimental mRNA vaccines also had the same issues as the viral vector vaccines [see Moderna and Pfizer are prone to blood clots too]. In addition, there have been a lot of deaths due to Moderna and Pfizer that have not been investigated. Is there a reason for this? It seems that there is a bias for the experimental mRNA vaccines. Why? [Read Vaccine injuries reach 56,869 – VAERS to see the devastating impacts of Pfizer and Moderna vaccines.]

Read Original Article

Read Online

Click the button below if you wish to read the article on the website where it was originally published.

Read Offline

Click the button below if you wish to read the article offline.

Bypass the censorship

Join 947 other subscribers

Information without censorship. Three emails per week, sometimes more. No Spam.

Leave a Reply

Your email address will not be published. Required fields are marked *